1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Disease Introduction 9
2.2 Epidemiology 10
2.3 Symptoms 11
2.4 Etiology and Pathophysiology 11
2.4.1 Autoimmune uveitis 12
2.4.2 Non-autoimmune uveitis 12
2.5 Diagnosis 14
2.6 Prognosis 15
2.7 Treatment Options 16
2.7.1 Corticosteroids 17
2.7.2 Immunosuppressive Agents 18
2.7.3 Biologics 18
2.7.4 Adjuvant Therapy 19

3 Marketed Products 20
3.1 Overview 20
3.1.1 Humira (adalimumab) - AbbVie 21
3.1.2 Retisert (fluocinolone acetonide) - Bausch & Lomb 22
3.1.3 Ozurdex (dexamethasone) - Allergan 23
3.1.4 Neoral (Cyclosporine) - Novartis 25
3.1.5 Mycept (Mycophenolate mofetil) - Panacea Biotec 26
3.1.6 Medrol (Methylprednisolone) - Pfizer 27
3.1.7 Betamethasone - Merck & Co. 28
3.1.8 Pred Forte (Prednisolone) - Allergan 28
3.2 Comparative Efficacy and Safety of Marketed Products 29

4 Pipeline Analysis 32
4.1 Overview 32
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 33
4.3 Pipeline by Molecular Target 34
4.4 Promising Pipeline Candidates 36
4.4.1 DE-109/ Opsiria (Sirolimus) - Santen 36
4.4.2 CLS-TA (triamcinolone acetonide) - Clearside BioMedical 37
4.5 Heatmap for Pipeline Products 38
4.6 Product Competitiveness Framework 40

5 Clinical Trial Analysis 42
5.1 Failure Rate 42
5.1.1 Overall Failure Rate 42
5.1.2 Failure Rate by Phase and Molecule Type 43
5.1.3 Failure Rate by Phase and Molecular Target 44
5.2 Clinical Trial Size 45
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 45
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 46
5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 47
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 48
5.3 Clinical Trial Duration 49
5.3.1 Trial Duration by Molecule Type and Stage of Development 49
5.3.2 Trial Duration by Molecular Target and Stage of Development 50
5.4 Summary of Clinical Trial Metrics 51

6 Multi-scenario Forecast 53
6.1 Geographical Markets 53
6.2 Asia-Pacific Market 53
6.2.1 Treatment Usage Patterns 53
6.2.2 Market Size 54
6.3 India 55
6.3.1 Treatment Usage Patterns 55
6.3.2 Annual Cost of Therapy 56
6.3.3 Market Size 57
6.4 China 58
6.4.1 Treatment Usage Patterns 58
6.4.2 Annual Cost of Therapy 59
6.4.3 Market Size 60
6.5 Australia 61
6.5.1 Treatment Usage Patterns 61
6.5.2 Annual Cost of Therapy 62
6.5.3 Market Size 63
6.6 South Korea 64
6.6.1 Treatment Usage Patterns 64
6.6.2 Annual Cost of Therapy 65
6.6.3 Market Size 66
6.7 Japan 67
6.7.1 Treatment Usage Patterns 67
6.7.2 Annual Cost of Therapy 68
6.7.3 Market Size 69

7 Drivers and Barriers 71
7.1 Drivers 71
7.1.1 Increasing Usage of Biologics 71
7.1.2 Promising Late-Stage Pipeline Products Can Change Treatment Paradigm 71
7.1.3 Increasing Elderly Population and Incidence of Uveitis 71
7.2 Barriers 71
7.2.1 Uveitis - An Under-Researched Disease 71
7.2.2 Low Diagnosis and Treatment Rates 72
7.2.3 Steep Prices of Therapeutics to Slow Down Market Growth 72

8 Deals and Strategic Consolidations 73
8.1 Licensing Deals 73
8.1.1 Deals by Region and Value 73
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 73
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 73
8.1.4 Key Licensing Deals 76
8.2 Co-development Deals 77
8.2.1 Deals by region, value, year, stage of development, molecule type and molecular target 77
8.2.2 Key Co-development Deals 77

9 Appendix 78
9.1 All Pipeline Drugs by Stage of Development 78
9.1.1 Discovery 78
9.1.2 Preclinical 78
9.1.3 IND/CTA-filed 79
9.1.4 Phase I 79
9.1.5 Phase II 80
9.1.6 Phase III 80
9.1.7 Pre-registration 80
9.2 Market Forecasts to 2023 81
9.2.1 Asia-Pacific 81
9.2.2 India 81
9.2.3 China 81
9.2.4 Australia 82
9.2.5 South Korea 82
9.2.6 Japan 83
9.3 Bibliography 83
9.4 Abbreviations 87
9.5 Research Methodology 88
9.5.1 Secondary Research 88
9.5.2 Marketed Product Profiles 88
9.5.3 Late-Stage Pipeline Candidates 88
9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products 88
9.5.5 Product Competitiveness Framework 89
9.5.6 Pipeline Analysis 89
9.5.7 Forecasting Model 90
9.5.8 Deals Data Analysis 91
9.6 Contact Us 91
9.7 Disclaimer 91

1.1 List of Tables
Table 1: Uveitis Therapeutics Market, APAC, Anatomic Classification of Uveitis 9
Table 2: Uveitis Therapeutics Market, APAC, Definition of Onset, Duration and Course of Uveitis 10
Table 3: Uveitis Therapeutics, APAC, Diseases Most Frequently Associated with Uveitis 13
Table 4: Uveitis Therapeutics, APAC, Investigations for Systemic Conditions Causing Uveitis 15
Table 5: Uveitis Therapeutics Market, APAC, Prognosis for Uveitis Patients 16
Table 6: Uveitis Therapeutics Market, Global, Licensing Deals with Disclosed Deal Value, 2006-2017 77
Table 7: Uveitis Therapeutics Market, Global, All Pipeline Products, Discovery, 2017 78
Table 8: Uveitis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017 78
Table 9: Uveitis Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2017 79
Table 10: Uveitis, Global, All Pipeline Products, Phase I, 2017 79
Table 11: Uveitis Therapeutics Market, Global, All Pipeline Products, Phase II, 2017 80
Table 12: Uveitis Therapeutics Market, Global, All Pipeline Products, Phase III, 2017 80
Table 13: Uveitis Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017 80
Table 14: Uveitis Therapeutics Market, Asia-Pacific, Market Forecast, 2016-2023 81
Table 15: Uveitis Therapeutics Market, India, Market Forecast, 2016-2023 81
Table 16: Uveitis Therapeutics Market, China, Market Forecast, 2016-2023 81
Table 17: Uveitis Therapeutics Market, Australia, Market Forecast, 2016-2023 82
Table 18: Uveitis Therapeutics Market, South Korea, Market Forecast, 2016-2023 82
Table 19: Uveitis Therapeutics Market, Japan, Market Forecast, 2016-2023 83

1.2 List of Figures
Figure 1: Uveitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Uveitis 31
Figure 2: Uveitis Therapeutics Market, Global, Pipeline, 2017 34
Figure 3: Uveitis Therapeutics Market, Global, Pipeline by Molecular Target, 2017 35
Figure 4: Uveitis Therapeutics Market, APAC, DE-109/Opsiria Market ($m), 2019-2023 37
Figure 5: Uveitis Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 39
Figure 6: Uveitis Therapeutics Market, Competitor Matrix for Uveitis Marketed and Pipeline Products, 2017 40
Figure 7: Uveitis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016 43
Figure 8: Uveitis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016 44
Figure 9: Uveitis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016 45
Figure 10: Uveitis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016 46
Figure 11: Uveitis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016 47
Figure 12: Uveitis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016 48
Figure 13: Uveitis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016 49
Figure 14: Uveitis Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016 50
Figure 15: Uveitis Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016 51
Figure 16: Uveitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 52
Figure 17: Uveitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 52
Figure 18: Uveitis Therapeutics Market, APAC, Treatment Patterns (‘000), 2016-2023 54
Figure 19: Uveitis Therapeutics Market, APAC, Market Size ($m), 2016-2023 55
Figure 20: Uveitis Therapeutics Market, India, Treatment Patterns (‘000), 2016-2023 56
Figure 21: Uveitis Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023 57
Figure 22: Uveitis Therapeutics Market, India, Market Size ($m), 2016-2023 58
Figure 23: Uveitis Therapeutics Market, China, Treatment Patterns (‘000), 2016-2023 59
Figure 24: Uveitis Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023 60
Figure 25: Uveitis Therapeutics Market, China, Market Size ($m), 2016-2023 61
Figure 26: Uveitis Therapeutics Market, Australia, Treatment Patterns (‘000), 2016-2023 62
Figure 27: Uveitis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023 63
Figure 28: Uveitis Therapeutics Market, Australia, Market Size ($m), 2016-2023 64
Figure 29: Uveitis Therapeutics Market, South Korea, Treatment Patterns (‘000), 2016-2023 65
Figure 30: Uveitis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023 66
Figure 31: Uveitis Therapeutics Market, South Korea, Market Size ($m), 2016-2023 67
Figure 32: Uveitis Therapeutics Market, Japan, Treatment Patterns (‘000), 2016-2023 68
Figure 33: Uveitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023 69
Figure 34: Uveitis Therapeutics Market, Japan, Market Size ($m), 2016-2023 70
Figure 35: Uveitis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 73
Figure 36: Uveitis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 74
Figure 37: Uveitis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017 75
Figure 38: Uveitis Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2017 76